Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03213145 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03213145 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT03213145, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human volunteers.
Interventions
- DRUG Rifampin
- DRUG EDP 305
- DRUG intraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2017-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03213145
The ClinicalTrials.gov registry entry for NCT03213145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT03213145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03213145 about?
NCT03213145 is a clinical study titled "Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers". This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human volunteers.
What is the current status of trial NCT03213145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-07-11. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT03213145?
The interventions under investigation include: Rifampin (DRUG), EDP 305 (DRUG), intraconazole (DRUG).
Who is sponsoring clinical trial NCT03213145?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.